FDA Facility Issue May Delay Regeneron's EYLEA HD Launch
FDA flags Catalent facility producing Regeneron's EYLEA HD syringe. Canaccord maintains $850 target, highlighting Alzheimer's pipeline potential and GLP-1 combos.
/ 1680 items
#XY↓
Tvardi's STAT3 Drug Misses Goals in Lung Disease Trial
Tvardi's TTI-101 lung drug trial failed. High GI side effects caused dropouts, and the drug showed no lung function benefit over placebo.
Citi Raises Arcus Biosciences Price Target to $54 on Promising Cancer Drug Data
Citi upgrades Arcus Biosciences price target to $54 following impressive Phase 2 cancer treatment results showing 26.7 months median survival in gastric cancer patients.
FDA Grants Breakthrough Status to Promising Head and Neck Cancer Treatment
Bicara Therapeutics' ficerafusp alfa receives FDA Breakthrough Therapy Designation for HPV-negative head and neck cancer, showing impressive response rates and survival benefits.
H.C. Wainwright Upgrades Karyopharm to Buy on Strategic Financing
H.C. Wainwright upgrades Karyopharm to Buy with $15 price target following strategic financing that extends cash runway beyond Phase 3 SENTRY trial results.
Mind Medicine Earns Bullish Analyst Coverage with $28 Price Target
Needham initiates Buy rating on Mind Medicine with $28 target, citing strong Phase 3 potential for MM120 treatment and $2.5B+ revenue opportunity in $12B market.